Please assess the completion status of the following clinical trial:

Trial Title: TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological proven, resectable squamous epithelial carcinoma of the oropharynx and the cavity of the mouth~2. R0-resection possible~3. All T N2 M0 / all T N3 M0 / if T3 or T4a also N0-1 M0~4. Leucocytes \> 4000/mm³ bzw. neutrophils \> 2000/mm³, thrombocytes \> 100000/mm³~5. adequate kidney function, defined as serum creatinine und urea in normal range, Creatinine clearance \> 60 ml/min~6. adequate liver function with glutamate oxaloacetate transaminase (SGOT), glutamate pyruvate transaminase (SGPT) and bilirubin in normal range~7. electrolytes in normal range~8. risks of anesthesia complications normal or minor increased~9. Eastern Cooperative Oncology Group (ECOG) 0-2 / Karnofsky \>= 60%~10. Age 18 - 80 years~11. signed written informed consent~12. effective contraception for both male and female subjects if the risk of conception exists~    Exclusion Criteria:~13. T1 N0 M0 / T1 N1 M0 / T2 N0 M0 / T2 N1 M0~14. Resection without curative intention: primary tumor is not treatable with resection methods~15. Infiltration of the lower jaw~16. M1 status~17. Tumor not measurable with Innovation Center Computer Assisted Surgery (ICCAS) methods~18. No prior chemotherapy or radiation (a primary surgery is allowed)~19. Metachronous or oder synchronous malignoma (Exception: basal cell carcinoma)~20. Life expectance \< 3 months~21. ECOG \> 2; Karnofsky \< 60%~22. acute infections or fever~23. known HIV-infection or other immune suppression~24. severe cardio pulmonary concomitant diseases~25. chronic disease with continuous therapy (uncontrolled diabetes, rheumatoid arthritis) especially continuous therapy with steroids~26. other concomitant diseases which, in the investigator's opinion, would exclude the patient from the study~27. Contraindications which permit a therapy with Docetaxel, Cisplatin, 5-FU or radiation therapy~28. missing patient's compliance~29. regular Follow-up visits not possible~30. Pregnancy or lactation period~31. legal incapacity or limited legal capacity~32. Participation in another clinical trial or administration of a not approved substance within 30 days before registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Taxotere, Cisplatin, 5-Fluorouracil (5-FU) (Type: EXPERIMENTAL): Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out.

Based on this trial design, predict the completion outcome and termination type (if applicable).